Lixte Biotechnology (LIXTW) News Today $0.03 +0.01 (+55.87%) (As of 11/25/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIESMarch 27, 2024 | finance.yahoo.comProfessor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer ResearchFebruary 27, 2024 | finance.yahoo.comLixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCIFebruary 26, 2024 | finanznachrichten.deLixte Biotechnology Holdings Inc (LIXT)February 1, 2024 | uk.investing.comLIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. KovachOctober 9, 2023 | finance.yahoo.comLixte Biotechnology Holdings, Inc.: LIXTE Appoints Bas van der Baan as President and Chief Executive OfficerSeptember 26, 2023 | finanznachrichten.deLIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian CancerSeptember 20, 2023 | finance.yahoo.com Get Lixte Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for LIXTW and its competitors with MarketBeat's FREE daily newsletter. Email Address The Great AI-Energy Collision (Ad)The biggest players in AI and tech are desperate to bring this limitless power source online. And fast. It’s the only way they can compete in their race for AI dominance. A handful of energy stocks are going to emerge from this transformation to dominate the sector. Get the full story here, while you still can. LIXTW Media Mentions By Week LIXTW Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LIXTW News Sentiment▼0.000.56▲Average Medical News Sentiment LIXTW News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LIXTW Articles This Week▼00▲LIXTW Articles Average Week Get Lixte Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for LIXTW and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alvotech News Today biote News Today BriaCell Therapeutics News Today Clever Leaves News Today Fortress Biotech News Today GeoVax Labs News Today LAVA Therapeutics News Today Mainz Biomed News Today Pharvaris News Today Procaps Group News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LIXTW) was last updated on 11/27/2024 by MarketBeat.com Staff From Our PartnersIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredA “Thank You Gift” From Pres. Trump - GeniusTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored140% Yields From Stocks Like Tesla? Here's How (Black Friday Special)140% Dividends from stocks like Tesla? Discover How for Just $9! For Black Friday, get the full details of ...Investors Alley | Sponsored9 hidden AI stocks set to thrive in Trump’s new eraAI ETFs are Booming, But These 9 AI Stocks are Better Plays By 2030, the AI industry is projected to be wor...StockEarnings | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lixte Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
